As discussed above, mineralocorticoid receptor antagonists (MRAs) have been demonstrated to attenuate or prevent development of renal failure, renal inflammation and fibrosis, by suppressing the over‐activation of the mineralocorticoid receptor in multiple animal models (Barrera‐Chimal et al., 2012; Du et al., 2009; Fujisawa et al., 2004; Ortiz et al., 2007; Taira et al., 2008). Here, NR3C2 is linked to Renal insufficiency.